Clinical Trial Update: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating multiple doses of iptacopan (LNP023) in adults with paroxysmal nocturnal hemoglobinuria to assess efficacy, safety, PK and PD; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Status: COMPLETED | Results posted: 2023-12-18